Antibacterial Drug Use and Bacterial Resistance in Psychiatric Hospitals During the 2022 Epidemic

Study Background and Research Question

The COVID-19 pandemic has posed unprecedented challenges to healthcare institutions worldwide, including psychiatric hospitals that must manage both mental health and complex infection risks. Psychiatric inpatients often present with impaired self-care, reduced immunity due to long-term psychotropic medication, and are managed in relatively closed community settings. This makes them especially vulnerable to bacterial infections, which can complicate treatment and recovery. Notably, the use of antibacterial drugs in these environments raises critical questions about optimal prescribing and the evolution of antimicrobial resistance (reference paper).

Key Innovation from the Reference Study

The referenced study by Jiang et al. provides one of the first comprehensive, data-driven assessments of antibacterial usage and bacterial resistance within a psychiatric hospital setting during the 2022 epidemic period. By leveraging both the hospital’s information system and the National Antibacterial Drug Clinical Application Monitoring Network, the researchers offer a rare, granular look at antibiotic utilization patterns, resistance profiles, and the implications for infection control in psychiatric care (reference paper).

Methods and Experimental Design Insights

The investigators performed a retrospective analysis using two primary data sources: the hospital’s internal information system and a national monitoring network. They extracted detailed statistics for the calendar year 2022, including:

• Antibiotic use rate and intensity (AUD)
• Combined medication rate
• Cumulative defined daily doses (DDDs)
• Microbiological submission rates for antibacterial drug use
• Bacterial species isolated and their drug sensitivity patterns

These data were benchmarked against provincial (Jiangsu) and national averages for contextual comparison. The main antibiotic classes and agents were identified, and resistance rates for both Gram-negative and Gram-positive pathogens were systematically recorded (reference paper).

Core Findings and Why They Matter

Key findings from the analysis include:

• Antibiotic Stewardship Success: The hospital’s antibiotic use rate (5.00%), intensity (3.07), and percentage of drug costs (3.95%) were all substantially lower than both provincial and national averages. This suggests a high degree of stewardship and restraint in antibiotic prescribing (reference paper).
• High Microbiological Submission Rate: The rate of microbiological samples submitted for antibiotic use was 77.78%, well above regional and national benchmarks. This indicates strong adherence to evidence-based, targeted therapy principles (reference paper).
• Resistance Patterns: Despite generally appropriate use, resistance among Gram-negative bacteria was most pronounced against penicillins, cephalosporins, and quinolones—especially ampicillin, amoxicillin–clavulanic acid, ceftazidime, ceftriaxone, amikacin, and ciprofloxacin. Gram-positive bacteria showed highest resistance to penicillins and macrolides, notably penicillin, benzylpenicillin, erythromycin, levofloxacin, and ciprofloxacin (reference paper).
• Complex Relationship: The study underscores a complex interplay between rational antibiotic use and the emergence of resistance, even in settings with lower-than-average antibiotic use. This suggests other factors—such as patient vulnerability and institutional management—contribute significantly to resistance development.

These findings emphasize the ongoing need for rigorous antimicrobial stewardship, targeted microbiological testing, and continuous surveillance of resistance trends in psychiatric settings, particularly during epidemics.

Comparison with Existing Internal Articles

While the reference study is focused on antibacterial drugs and resistance, several internal articles highlight related mechanisms of immune modulation and anti-inflammatory research relevant to infection control. For instance, internal resources such as "Gamma-linolenic Acid (GLA) in Immune Modulation and LTB4..." and "Gamma-linolenic acid (GLA): Benchmarks, Mechanisms, and A..." discuss the translational potential of GLA—an omega-6 polyunsaturated fatty acid and weak leukotriene B4 receptor antagonist—for modulating inflammatory processes and apoptosis. Although these articles do not directly address antibacterial resistance, they provide mechanistic context for adjunctive strategies to mitigate inflammation-induced tissue damage, which is relevant in psychiatric populations susceptible to infection and immune dysregulation (internal_article). Similarly, the internal article "Gamma-linolenic acid: Optimizing Anti-Inflammatory Workflows" outlines how GLA can be integrated into apoptosis assays and anti-inflammatory workflows, supporting research into host-pathogen interactions and immune homeostasis. These resources underscore the value of cross-disciplinary approaches in understanding and managing infection risks beyond antibiotic therapy alone (internal_article).

Limitations and Transferability

Despite its strengths, the study is limited by its single-center, retrospective design and focus on one calendar year within a specific epidemic context. The findings may not generalize to all psychiatric hospitals, especially those with different patient demographics or management protocols. Furthermore, resistance trends are influenced by local epidemiology, infection control practices, and broader healthcare system factors. Nevertheless, the methodological rigor and benchmarking approach provide a valuable template for similar analyses in other institutional settings (reference paper).

Protocol Parameters

• antibiotic use rate | 5.00% | psychiatric inpatients | reflects stewardship; below regional/national averages | paper
• antibiotic use intensity (AUD) | 3.07 | psychiatric inpatients | indicates low usage burden | paper
• microbiological submission rate | 77.78% | antibiotic prescriptions | enables targeted therapy | paper
• cumulative DDDs | 12,039.04 | annual hospital data | quantifies total exposure | paper
• antibiotic cost proportion | 3.95% | annual drug budget | supports cost-effectiveness | paper
• GLA, apoptosis assay | 0.087 mM (IC50 in HL60) | in vitro cytotoxicity | supports apoptosis and anti-inflammatory research | product_spec
• GLA, LTB4 receptor inhibition | Ki ~1 μM | neutrophil membrane binding | models anti-inflammatory mechanisms | product_spec
• GLA, in vivo bronchoconstriction inhibition | 53% at 1 mg/kg | animal models | demonstrates anti-inflammatory efficacy | product_spec
• GLA, recommended storage | -20°C | reagent stability | preserves molecular integrity | product_spec
• GLA, solubility | up to 100 mg/ml in DMSO/DMF | assay prep | enables flexible workflow design | product_spec

Research Support Resources

Researchers seeking to extend infection and inflammation studies in psychiatric or other institutional settings may benefit from integrating additional anti-inflammatory and immune-modulating agents into their assays. For example, Gamma-linolenic acid (GLA) (SKU C5518) is a well-characterized omega-6 polyunsaturated fatty acid, available from APExBIO, that acts as a weak leukotriene B4 receptor antagonist and exhibits robust anti-inflammatory and cytotoxic properties (source: product_spec). GLA can be utilized in cell-based apoptosis assays, inflammation models, or as a reference compound for anti-inflammatory research in vitro and in vivo. For protocol-specific parameters and workflow integration, see product guidelines and peer-reviewed reference data (source: product_spec).